MiNK Therapeutics, Inc. (INKT) stock
INKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$9.29−0.06 (-0.70%)
Close on Nov 17, 2026Market cap $47.38MP/E –Yield –
MiNK Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
MiNK Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.75M, up 13.9% year over year. For fiscal 2025 it was $5.76M, down 9.1% from the year before. The highest annual figure on record is $23.12M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.76M | -9.1% |
| FY2024 | Dec 31, 2024 | $6.34M | -59.1% |
| FY2023 | Dec 31, 2023 | $15.49M | -33.0% |
| FY2022 | Dec 31, 2022 | $23.12M | +65.5% |
| FY2021 | Dec 31, 2021 | $13.97M | +46.9% |
| FY2020 | Dec 31, 2020 | $9.51M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.89M | +2.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.20M | -4.6% |
| Q4 FY2025 | Dec 31, 2025 | $1.51M | +7.6% |
| Q3 FY2025 | Sep 30, 2025 | $1.14M | +111.4% |
| Q2 FY2025 | Jun 30, 2025 | $1.84M | -0.0% |
| Q1 FY2025 | Mar 31, 2025 | $1.26M | -50.5% |
| Q4 FY2024 | Dec 31, 2024 | $1.41M | -57.5% |
| Q3 FY2024 | Sep 30, 2024 | $540.64K | -84.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.84M | -59.6% |
| Q1 FY2024 | Mar 31, 2024 | $2.55M | -39.2% |
| Q4 FY2023 | Dec 31, 2023 | $3.31M | -43.0% |
| Q3 FY2023 | Sep 30, 2023 | $3.43M | -44.3% |
| Q2 FY2023 | Jun 30, 2023 | $4.56M | -22.4% |
| Q1 FY2023 | Mar 31, 2023 | $4.19M | -20.5% |
| Q4 FY2022 | Dec 31, 2022 | $5.81M | +47.1% |
| Q3 FY2022 | Sep 30, 2022 | $6.15M | +84.4% |
| Q2 FY2022 | Jun 30, 2022 | $5.88M | +63.9% |
| Q1 FY2022 | Mar 31, 2022 | $5.28M | +70.4% |
| Q4 FY2021 | Dec 31, 2021 | $3.95M | +401.4% |
| Q3 FY2021 | Sep 30, 2021 | $3.33M | +33.2% |
| Q2 FY2021 | Jun 30, 2021 | $3.58M | – |
| Q1 FY2021 | Mar 31, 2021 | $3.10M | – |
| Q4 FY2020 | Dec 31, 2020 | $787.82K | – |
| Q3 FY2020 | Sep 30, 2020 | $2.50M | – |
See a number that looks wrong?